Novavax (NASDAQ:NVAX) Earns Buy Rating from Analysts at HC Wainwright

Key Points

• HC Wainwright has reaffirmed a "Buy" rating for Novavax (NASDAQ: NVAX), with a price target of $10.00, suggesting a potential upside of 31.93% from its current price.
• Bank of America and JPMorgan Chase have issued underperform ratings and lower price targets, indicating a more cautious outlook among some analysts.
• Novavax reported earnings of $0.62 per share, significantly exceeding expectations, despite a 42.4% revenue decline compared to the previous year.

HC Wainwright initiated coverage on shares of Novavax (NASDAQ:NVAX - Get Free Report) in a research note issued to investors on Thursday, Marketbeat reports. The brokerage set a "buy" rating and a $10.00 price target on the biopharmaceutical company's stock. HC Wainwright's price target indicates a potential upside of 33.87% from the company's current price. HC Wainwright also issued estimates for Novavax's Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.37) EPS and FY2026 earnings at ($0.68) EPS.

Several other brokerages also recently commented on NVAX. B. Riley reiterated a "buy" rating on shares of Novavax in a report on Monday, May 19th. Bank of America reissued an "underperform" rating and issued a $7.00 price objective (down from $9.00) on shares of Novavax in a research report on Wednesday, August 20th. JPMorgan Chase & Co. reduced their price objective on Novavax from $9.00 to $7.00 and set an "underweight" rating for the company in a research report on Friday, May 9th. Finally, Citigroup began coverage on Novavax in a research report on Tuesday, June 17th. They issued a "sell" rating and a $6.00 price objective for the company. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Novavax has an average rating of "Hold" and an average target price of $14.29.

Novavax Stock Performance

NVAX traded down $0.11 during trading on Thursday, hitting $7.47. The stock had a trading volume of 6,385,474 shares, compared to its average volume of 9,394,446. The firm has a market cap of $1.21 billion, a PE ratio of 3.28, a P/E/G ratio of 0.10 and a beta of 2.50. Novavax has a 12 month low of $5.01 and a 12 month high of $15.22. The company has a current ratio of 2.36, a quick ratio of 2.34 and a debt-to-equity ratio of 5.93. The company has a 50 day simple moving average of $7.40 and a 200-day simple moving average of $7.17.

Novavax (NASDAQ:NVAX - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.69. The firm had revenue of $239.24 million for the quarter, compared to the consensus estimate of $149.19 million. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The business's quarterly revenue was down 42.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.99 EPS. Analysts expect that Novavax will post -1.46 EPS for the current year.

Hedge Funds Weigh In On Novavax

Hedge funds and other institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new position in shares of Novavax during the 4th quarter worth about $27,000. State of Wyoming bought a new position in shares of Novavax during the 2nd quarter worth about $52,000. Signaturefd LLC lifted its holdings in shares of Novavax by 47.2% during the 2nd quarter. Signaturefd LLC now owns 9,739 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 3,122 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in shares of Novavax during the 2nd quarter worth about $73,000. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Novavax during the 1st quarter worth about $71,000. 53.04% of the stock is owned by institutional investors.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.